Anti-tumor therapeutic effects in mice treated with Listeria monocytogenes (Lm)-LLO immunotherapy in combination with PD-L1

被引：0
|
作者：
Molli, Poonam [1 ]
Wallecha, Anu [1 ]
机构：
[1] Advaxis Inc, Princeton, NJ USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-2513
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2513
引用
收藏
页数：1
相关论文
共 50 条
  • [21] MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
    Ebert, Peter J. R.
    Cheung, Jeanne
    Yang, Yagai
    McNamara, Erin
    Hong, Rebecca
    Moskalenko, Marina
    Gould, Stephen E.
    Maecker, Heather
    Irving, Bryan A.
    Kim, Jeong M.
    Belvin, Marcia
    Mellman, Ira
    IMMUNITY, 2016, 44 (03) : 609 - 621
  • [22] PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
    Liu, Jinhua
    Chen, Zichao
    Li, Yaqun
    Zhao, Wenjie
    Wu, JiBiao
    Zhang, Zhen
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [23] Alterations in PD-L1 succinylation shape anti-tumor immune responses in melanoma
    Liang, Long
    Kuang, Xinwei
    He, Yi
    Zhu, Lin
    Lau, Poyee
    Li, Xin
    Luo, Dingan
    Gong, Lan
    Zhou, Wenbin
    Zhang, Fanglin
    Liang, Xiaowei
    Li, Zhuofeng
    Hu, Bin
    Liu, Dandan
    Ding, Tao
    Li, Hui
    Zhao, Shuang
    Su, Juan
    Hung, Mien-Chie
    Liu, Jing
    Liu, Hong
    Chen, Xiang
    NATURE GENETICS, 2025, 57 (03) : 680 - 693
  • [24] Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
    Poggio, Mauro
    Hu, Tianyi
    Pai, Chien-Chun
    Chu, Brandon
    Belair, Cassandra D.
    Chang, Anthony
    Montabana, Elizabeth
    Lang, Ursula E.
    Fu, Qi
    Fong, Lawrence
    Blelloch, Robert
    CELL, 2019, 177 (02) : 414 - +
  • [25] Novel Strategy to Regulate PD-L1 Expression and Enhance Anti-Tumor Effect
    Sredni, Benjamin
    Chaouat, Abigael
    Hay, Ophir
    Manoim, Julia
    Nadler, Ronia
    Kalechman, Yona
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [26] DNMT1 constrains IFNβ-mediated anti-tumor immunity and PD-L1 expression to reduce the efficacy of radiotherapy and immunotherapy
    Huang, Kevin Chih-Yang
    Chiang, Shu-Fen
    Ke, Tao-Wei
    Chen, Tsung-Wei
    Hu, Ching-Han
    Yang, Pei-Chen
    Chang, Hsin-Yu
    Liang, Ji-An
    Chen, William Tzu-Liang
    Chao, K. S. Clifford
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [27] Targeting the intrinsic signaling of PD-L1 in human monocytes by a novel PD-L1 antibody to promote anti-tumor immunity.
    Hsu, Michelle A.
    Liu, Xin
    Barham, Whitney
    Hirdler, Jacob
    Mao, Zhiming
    Lucien, Fabrice
    Dong, Haidong
    JOURNAL OF IMMUNOLOGY, 2023, 210 (01):
  • [28] PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy
    Karwacz, Katarzyna
    Arce, Frederick
    Bricogne, Christopher
    Kochan, Grazyna
    Escors, David
    ONCOIMMUNOLOGY, 2012, 1 (01): : 86 - 88
  • [29] Formin protein DIAPH1 positively regulates PD-L1 expression and predicts the therapeutic response to anti-PD-1/PD-L1 immunotherapy
    Mei, Jie
    Cai, Yun
    Wang, Huiyu
    Xu, Rui
    Zhou, Jiaofeng
    Lu, Jiahui
    Yang, Xuejing
    Pan, Jiadong
    Liu, Chaoying
    Xu, Junying
    Zhu, Yichao
    CLINICAL IMMUNOLOGY, 2023, 246
  • [30] Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-1/PD-L1 immunotherapy
    Hu, Weixian
    THORACIC CANCER, 2020, 11 (01) : 3 - 5
12345